Heracles Pharma Seeks to Develop Strategic Partnerships with Pharmaceutical Industry in Pursuit of FDA Approval and Commercialization of X-22 Very Low Nicotine Smoking Cessation Product CLARENCE, N.Y.– XXII, (BUSINESS WIRE)– 22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that 22nd Century has launched a new website atwww.heraclespharma.com to highlight the Company’s X-22 Very Low Nicotine smoking cessation cigarette in development. With 95% less nicotine than conventional tobacco, X-22Read more
- Vertically integrated cannabis firm Ascend Wellness raises $55 million for expansion
- Lifeline Biotechnologies Updates Shareholders and The Public
- Financial Gravity Selects Securities Transfer Corporation as Transfer Agent
- Wayfair Reports 58% Increase in Direct Retail Sales for Peak Five-Day Holiday Shopping Weekend
- Marijuana tech firm Metrc gets $50M with help from Snoop Dogg, Tiger Global
SMALL CAP MARKET NEWS
We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.
LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!
Stock Investors · Accredited Investors · Hedge Fund InvestorsLearn More